- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
NPPA fixes price for various FDCs having Sitagliptin, Linagliptin
New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has announced that it has fixed retail prices of 39 formulations under the Drugs (Prices Control) Order, 2013. The price fixation is based on the decision of the 120th Authority meeting dated 24.01.2024.
The formulations whose prices have been fixed include Prosperity Drugs and Torrent Pharma's Paracetamol and Dicyclomine Hydrochloride Tablets, Abbott India's Zolpidem Tartrate Prolonged release tablets, Pure and cure Healthcare and Dr Reddy's Labs's Rosuvastatin plus Clopidogrel Capsules, Curetech Skincare and J.B. Chemicals & Pharma's Diclofenac Diethylamine, Virgin Linseed Oil, Methyl Salicylate, Menthol & Capsacin Gel.
The list further includes Synokem Pharmaceuticals and Mankind Pharma's Linagliptin, Metformin Hydrochloride (Extended Release) Tablets, Mascot Health Series and Lupin's Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets, Sun Pharma Laboratories's Dapagliflozin, Metformin Hydrochloride Extended Releaseand Glimepiride Tablets.
This comes in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Paracetamol and Dicyclomine Hydrochloride Tablets | Each uncoated tablet contains: Paracetamol IP 325mg Dicyclomine Hydrochloride IP 20mg | 1 Tablet | M/s Prosperity Drugs Pvt. Ltd. / M/s Torrent Pharmaceuticals Limited |
2.12 |
2 | Albendazole & Ivermectin Suspension | Each 5ml contains: Albendazole IP 200mg Ivermectin IP 3mg | 1 ml | M/s. Prochem Pharmaceuticals Pvt. Ltd. / M/s Indoco Remedies Limited |
1.36 |
3 | Amoxycillin and Potassium Clavulanate Oral Suspension | Each 5ml of reconstituted suspension contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 600mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 42.9mg | 1 ml | M/s Alps Communication Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd. |
3.17 |
4 | Cefuroxime Axetil & Potassium Clavulanate IP Tablets | Each film coated tablet contains: Cefuroxime Axetil IP eq. to Anhydrous Cefuroxime 500mg Potassium Clavulanate Diluted IP Eq. to Clavulanic Acid 125mg | 1 Tablet | M/s Theon Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd. | 56.98 |
5 | Amoxycillin and Potassium Clavulanate Tablets IP | Each film coated tablet contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 875mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125mg |
1 Tablet | M/s Brooks Laboratories Ltd. / M/s German Remedies Pharmaceuticals Private Limited |
40.03 |
6 | Zolpidem Tartrate Prolonged release tablets | Each film coated bilayered Prolonged release tablets contains: Zolpidem Tartrate IP 12.50mg |
1 Tablet |
M/s Abbott India Limited |
14.12 |
7 | Zolpidem Tartrate Prolonged release tablets | Each film coated bilayered Prolonged release tablets contains: Zolpidem Tartrate IP 6.25mg |
1 Tablet |
M/s Abbott India Limited |
11.41 |
8 | Meropenem and Sulbactum for Injection | Each vial contains: Meropenem IP (Sterile) eq. to Anhydrous Meropenem 1000mg Sodium Carbonate IP (As buffer) eq. to Sodium 90.2mg Sulbactam Sodium IP (Sterile) eq. to Sulbactum 500mg |
1 vial |
M/s Aqua Vitoe Laboratories / M/s FDC Limited |
1584.2 4 |
9 | Rosuvastatin + Clopidogrel Capsules | Each Hard gelatin capsule contains: Rosuvastatin Calcium IP Eq. to Rosuvastatin 20mg (As film coated Tablet form)Clopidogrel Bisulphate IP Eq. to Clopidogrel 75mg (As Film coated Tablet form) |
1 Capsule |
M/s Pure and cure Healthcare Pvt. Ltd. / Dr. Reddy's Laboratories Limited |
19.21 |
10 | Diclofenac Diethylamine, Virgin Linseed Oil, Methyl Salicylate, Menthol & Capsacin Gel | Contains: Diclofenac Diethylamine IP 1.16% w/w, Virgin Linseed Oil BP 3% w/w, Methyl Salicylate 10% w/w, Menthol IP 5% w/w Capsacin USP 0.025% w/w |
1 gram |
M/s Curetech Skincare / M/s J.B. Chemicals & Pharmaceuticals Ltd. |
3.41 |
11 | Omeprazole & Domperidone Capsules IP | Each hard gelatin capsule contains: Omeprazole IP 20mg (as enteric coated pallets) Domperidone IP 10mg |
1 Capsule | M/s Innova Captab Limited / M/s Eris Healthcare Pvt. Ltd. |
6.18 |
12 | Linagliptin, Metformin Hydrochloride (Extended Release) Tablets | Each film coated bilayered tablet contains: Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg (As Extended Release) |
1 Tablet | M/s Synokem Pharmaceuticals Limited / M/s Mankind Pharma Limited |
9.18 |
13 | Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 1 mg |
1 Tablet |
M/s Exemed Pharmaceuticals / M/s Micro Labs Limited |
11.61 |
14 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 1 mg |
1 Tablet |
M/s Mascot Health Series Pvt. Ltd. / M/s Lupin Limited |
13.35 |
15 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 1 mg |
1 Tablet |
M/s Exemed Pharmaceuticals / M/s Abbott Healthcare Pvt. Ltd. |
13.35 |
16 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 1 mg |
1 Tablet |
M/s Synokem Pharmaceuticals Ltd. / M/s Mankind Pharma Limited |
13.35 |
17 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 1 mg |
1 Tablet |
M/s Exemed Pharmaceuticals / M/s Glenmark Pharmaceuticals Limited |
13.35 |
18 | Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 1 mg |
1 Tablet |
M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited |
13.35 |
19 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 1 mg |
1 Tablet |
M/s Exemed Pharmaceuticals / M/s Torrent Pharmaceuticals Limited |
13.35 |
20 | Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 1 mg |
1 Tablet | M/s Exemed Pharmaceuticals / M/s Eris Lifesciences Limited |
13.35 |
21 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 1 mg |
1 Tablet |
M/s Synokem Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Limited |
13.35 |
22 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 1 mg |
1 Tablet |
M/s Exemed Pharmaceuticals / M/s Dr. Reddy’s Laboratories Limited |
13.35 |
23 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg |
1 Tablet |
M/s Exemed Pharmaceuticals / M/s Micro Labs Limited |
13.39 |
24 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg |
1 Tablet |
M/s Exemed Pharmaceuticals / M/s Abbott Healthcare Pvt. Ltd. |
15.03 |
25 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg |
1 Tablet |
M/s Exemed Pharmaceuticals / M/s Glenmark Pharmaceuticals Limited |
15.03 |
26 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg |
1 Tablet |
M/s Synokem Pharmaceuticals Ltd. / M/s Mankind Pharma Limited |
15.03 |
27 | Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Lupin Limited | 15.03 |
28 | Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg |
1 Tablet |
M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited |
15.03 |
29 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg |
1 Tablet |
M/s Exemed Pharmaceuticals / M/s Torrent Pharmaceuticals Limited |
14.30 |
30 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg |
1 Tablet |
M/s Synokem Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Limited |
14.30 |
31 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg |
1 Tablet |
M/s Exemed Pharmaceuticals / M/s Dr. Reddy’s Laboratories Limited |
15.03 |
32 |
Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg |
1 Tablet |
M/s Exemed Pharmaceuticals / M/s Eris Lifesciences Limited |
15.03 |
33 | Dapagliflozin, Metformin Hydrochloride Extended Releaseand Glimepiride Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As extended release) Glimepiride IP 2 mg |
1 Tablet |
M/s Sun Pharma Laboratories Limited |
15.15 |
34 | Dapagliflozin, Metformin Hydrochloride Extended Releaseand Glimepiride Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 500mg (As extended release) Glimepiride IP 1 mg |
1 Tablet |
M/s Sun Pharma Laboratories Limited |
13.47 |
35 |
Dapagliflozin, Metformin Hydrochloride Extended Releaseand Glimepiride Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As extended release) Glimepiride IP 2 mg |
1 Tablet |
M/s Sun Pharma Laboratories Limited |
16.00 |
36 |
Dapagliflozin, Metformin Hydrochloride Extended Releaseand Glimepiride Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Metformin Hydrochloride IP 1000mg (As extended release) Glimepiride IP 1 mg | 1 Tablet | M/s Sun Pharma Laboratories Limited | 14.50 |
37 | Linagliptin + Metformin Hydrochloride (ER) Tablet | Each film coated bilayered tablet contains: Linagliptin 5mg Metformin Hydrochloride IP 1000mg (as Extended release) | 1 Tablet | M/s Exemed Pharmaceuticals Ltd. / M/s USV Private Limited |
14.37 |
38 | Linagliptin + Metformin Hydrochloride (ER) Tablet | Each film coated bilayered bilayered tablet contains: Linagliptin 5mg Metformin Hydrochloride (as Extended release) IP 1000mg | 1 Tablet | M/s Synokem Pharmaceuticals Ltd. / M/s Emcure Pharmaceuticals Limited | 14.72 |
39 | Linagliptin + Metformin Hydrochloride (ER) Tablet | Each film coated tablet contains: Linagliptin 5mg Metformin Hydrochloride (as Extended release) IP 1000mg | 1 Tablet | M/s Exemed Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt. Ltd. | 11.61 |
Note:
(a) The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer/ marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
To view more, click on the official notice:
https://medicaldialogues.in/pdf_upload/retail-engl-hindi-231719.pdf
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751